Search results for: oncology
-
Effect of brefeldin A and castanospermine on resistant cell lines as supplements in anticancer therapy
Publication -
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Publication -
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Publication -
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network†
Publication -
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients
Publication -
Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results
Publication -
Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers
Publication -
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Publication -
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
Publication -
Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients
Publication -
Regarding the “Tumour spillage of the pleomorphic adenoma of the parotid gland: A proposal for intraoperative measures”
Publication -
Regarding the concurrent presence of secretory carcinoma and Warthin’s tumor in the ipsilateral parotid gland
Publication -
Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency
PublicationAccording to the WHO, cancer is the second leading cause of death in the world. This is an important global problem and a major challenge for researchers who have been trying to find an effective anticancer therapy. A large number of newly discovered compounds do not exert selective cytotoxic activity against tumorigenic cells and have too many side effects. Therefore, research on muramyl dipeptide (MDP) analogs has attracted interest...
-
imPlatelet classifier: image‐converted RNA biomarker profiles enable blood‐based cancer diagnostics
PublicationLiquid biopsies offer a minimally invasive sample collection, outperforming traditional biopsies employed for cancer evaluation. The widely used material is blood, which is the source of tumor-educated platelets. Here, we developed the imPlatelet classifier, which converts RNA-sequenced platelet data into images in which each pixel corresponds to the expression level of a certain gene. Biological knowledge from the Kyoto Encyclopedia...
-
Prognostic factors in postoperative radiotherapy for prostate cancer – tertiary center experience
Publication -
MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma
Publication -
Correlation between Early Treatment Failure and Ki67 Antigen Expression in Blast Cells of Children with Acute Lymphoblastic Leukaemia before Commencing Treatment
Publication -
A link between seasonality and radiation-related toxicity: The big time or time will tell?
Publication -
Regarding the “The spiral ladder technique of facial nerve trunk identification during parotidectomy: A convenient roadmap for the beginners”
Publication -
DNA-reactive anticancer imidazoacridinone C-1311 is a new inhibitor of hypoxia-inducible factor 1 alpha, vascular endothelial growth factor and tumor angiogenesis
PublicationHypoxia-inducible factor 1 (HIF-1) plays a critical role for tumor adaptation to hypoxia and promotes angiogenesis. Antitumor imidazoacridinone C-1311 is a DNA reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor selected for phase II clinical trials for breast cancer. Here, we demonstrate the new mechanism of C-1311 action involving HIF-1a, vascular endothelial growth factor (VEGF) and angiogenesis as additional...
-
Improving platelet‐RNA‐based diagnostics: a comparative analysis of machine learning models for cancer detection and multiclass classification
PublicationLiquid biopsy demonstrates excellent potential in patient management by providing a minimally invasive and cost-effective approach to detecting and monitoring cancer, even at its early stages. Due to the complexity of liquid biopsy data, machine-learning techniques are increasingly gaining attention in sample analysis, especially for multidimensional data such as RNA expression profiles. Yet, there is no agreement in the community...
-
Recent advances in 3D bioprinted tumor models for personalized medicine
PublicationCancerous tumors are among the most fatal diseases worldwide, claiming nearly 10 million lives in 2020. Due to their complex and dynamic nature, modeling tumors accurately is a challenging task. Current models suffer from inadequate translation between in vitro and in vivo results, primarily due to the isotropic nature of tumors and their microenvironment's relationship. To address these limitations, hydrogel-based 3D bioprinting...
-
Differential ability of cytostatics from anthraquinone group to generatefree radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xantine oxidase.
PublicationZbadano szereg cytostatyków z grupy antrachinonu pod względem ich zdolności do pośredniczenia w przeniesieniu jednoelektronowym i generowaniu wolnych rodników tlenowych pod wpływem trzech oksydoreduktaz. Zdefiniowano czynniki strukturalne związków odpowiedzialne za ten proces katalizowany przez poszczególne enzymy.
-
Current situation in Polish nuclear medicine and Polish example of model Nuclear Medicine Centre meeting European Union requirements
PublicationNuclear medicine is currently a well-established part of medicine. It is applied in many fields of clinical medicine and science like endocrinology, oncology, cardiology, molecular medicine and engineering, radiopharmacy, physics and information science. Due to its increasing importance and application, several regulation and supervision bodies have been founded to ensure safe usage of radiation and to improve diagnostic and therapeutic...
-
Why they want to be treated in clinical trial -fundamental reasons of patient's decision
Publication -
PUB073 Lung Cancer Screening with LDCT – Results of a Small Cohort Continual Monitoring (Pilot Silesian Study)
Publication -
P3.13-032 The Impact of Tobacco Exposure on Lung Nodules and Emphysema in a Pilot Silesian Study of Early Lung Cancer with LDCT
Publication -
Retrospective assessment of Lung-RADS® performance in the Silesian Lung Cancer Screening Pilot Study
Publication -
The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma
Publication -
The Relationship of Purpose in Life and Hope in Shaping Happiness Among Patients with Cancer in Poland
Publication -
Molecular differences in mitochondrial DNA genomes of dogs with malignant mammary tumours
Publication -
Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies
Publication -
Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: Association with tumor progression
Publication -
High- and low-Molecular Weight oat Beta-Glucan Reveals Antitumor Activity in Human Epithelial Lung Cancer
Publication -
Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture
Publication -
Chirurgiczne leczenie chorych na raka pęcherzyka żółciowego: doświadczenia własne na podstawie 16 przypadków
Publication -
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Publication -
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Publication -
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Publication -
Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer
Publication -
Identification of High-Risk Stage II Colorectal Tumors by Combined Analysis of the NDRG1 Gene Expression and the Depth of Tumor Invasion
Publication -
Complementary and alternative medicine (CAM) use among patients with cancer undergoing palliative care: A pilot study of a single institution in Poland.
Publication -
Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer
Publication -
Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non–muscle-invasive Bladder Cancer
Publication -
Zastosowanie metod termograficznych w ocenie obrzęku limfatycznego kończyny górnej u chorych po amputacji piersi z powodu raka
Publication.
-
Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies
PublicationAbstract Background IDH-wildtype glioblastoma (GBM) is a highly malignant primary brain tumor with a median survival of 15 months after standard of care, which highlights the need for improved therapy. Personalized combination therapy has shown to be successful in many other tumor types and could be beneficial for GBM patients. Methods We performed the largest drug combination screen to date in GBM, using a high-throughput effort...
-
Longitudinal drug synergy assessment using convolutional neural network image-decoding of glioblastoma single-spheroid cultures
PublicationAbstract Background In recent years, drug combinations have become increasingly popular to improve therapeutic outcomes in various diseases, including difficult to cure cancers such as the brain cancer glioblastoma. Assessing the interaction between drugs over time is critical for predicting drug combination effectiveness and minimizing the risk of therapy resistance. However, as viability readouts of drug combination experiments...
-
A 10-Year-old Girl With Late Acute Lymphoblastic Leukemia Recurrence Diagnosed With COVID-19 and Treated With Remdesivir
Publication -
292. Cisplatin and 5-fluorouracil in recurrent, persistent or metastatic cervical carcinoma
Publication -
Clinical Presentation of Herpes Zoster in Immunocompetent and Immunocompromised Hospitalized Children Treated With Acyclovir
Publication